AstraZeneca stocks drop 3% as results of early-stage study on coronavirus vaccine released

Shares of AstraZeneca AZN,
-0.75%
AZN
+ 3.16%
They fell 3.4% in trade on Monday after a medical journal published a study that found the company’s COVID-19 vaccine candidate produced antibody and T-cell responses in participants in a phase 1/2 clinical trial. . AstraZeneca is developing the experimental vaccine with the University of Oxford; The study was published in The Lancet. The single-blind, randomized controlled trial found that neutralizing antibody responses were reported in 91% of 35 patients when using one test and in 100% of 35 patients when using a different test. He also found that T-cell responses peaked on day 14. “A single dose elicited humoral and cellular responses against SARS-CoV-2, with a booster immunization that increases neutralizing antibody titers,” they wrote. the study authors. BioNTech BNTX,
+ 4.24%
and Pfizer Inc. PFE,
+ 1.80%,
who are also developing a COVID-19 vaccine, said Monday that their vaccine candidate produced a T-cell response in participants of an early-stage trial in Germany. AstraZeneca shares have gained 21.3% so far this year, compared to the S&P 500 SPX,
+ 0.27%,
which fell 0.2%.